Ashwin Iyer,Aishwarya Gurumurthy,Alec Chu,Rohan Kodgule,Athalee R. Aguilar,Travis Saari,Abdullah Ramzan,Jan Rosa,Juhi Gupta,Arvind Emmanuel,Cody N. Hall,John S. Runge,Anna B. Owczarczyk,Jang Hwan Cho,Matthew B. Weiss,Rockwell Anyoha,Kristin Sikkink,Savanna Gemus,Charles P. Fulco,Anamarija M. Perry
出处
期刊:Blood cancer discovery [American Association for Cancer Research] 日期:2025-03-11
标识
DOI:10.1158/2643-3230.bcd-24-0126
摘要
Abstract High expression of MYC and its target genes identify germinal center B-cell diffuse large B-cell lymphomas (GCB-DLBCL) associated with poor outcomes. We used CRISPR-interference profiling of human lymphoma cell lines to define essential enhancers in the MYC locus and non-immunoglobulin rearrangement partner loci, including a recurrent rearrangement between MYC and the BCL6 locus control region. GCB-DLBCL cell lines without MYC rearrangement are dependent on an evolutionarily-conserved enhancer we name “germinal center MYC enhancer 1” (GME-1), which is activated by the transcription factor complex of OCT2, OCA-B, and MEF2B, shows an active chromatin state in normal human and mouse germinal center B cells, and demonstrates selective acetylation and MYC promoter topological interactions in MYC-intact GCB-DLBCL biopsies. Whole-genome sequencing identified tandem copy gains of the GME-1 enhancer as a rare but recurrent event in DLBCL. Our findings shed new light on mechanisms that dysregulate MYC, a key driver of B cell malignancy.